1. Clinical outcomes and adverse effect monitoring in allergic rhinitis
Elizabeth F. Juniper, MCSP, MSc, Elisabeth Ståhl, PhD, Richard L. Doty, MD, PhD, F. Estelle R. Simons, MD, FRCPC, David B. Allen, MD, Peter H. Howarth, BSc (Hons), DM, FRCP 
Journal of Allergy and Clinical Immunology 
Volume 115, Issue 3, Pages S390-S413 (March 2005)
DOI: /j.jaci
Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

2. Fig 1
Improvement in RQLQ score with budesonide aqueous nasal spray (BANS) at 2 dose levels in comparison with placebo in perennial allergic rhinitis. NS, not significant. Adapted from Ståhl et al.13
Journal of Allergy and Clinical Immunology  , S390-S413DOI: ( /j.jaci )
Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

3. Fig 2
Improvement in RQLQ score with fexofenadine compared with placebo and loratadine in seasonal allergic rhinitis. NS, not significant. Reproduced with permission from Blackwell Publishing.11
Journal of Allergy and Clinical Immunology  , S390-S413DOI: ( /j.jaci )
Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

4. Fig 3
Improvement in individual QOL domains in seasonal allergic rhinitis with anti-IgE mAb therapy (omilizumab) in comparison with placebo. Adapted from Adelroth et al.37
Journal of Allergy and Clinical Immunology  , S390-S413DOI: ( /j.jaci )
Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

5. Fig 4
UPSIT. This 40-odorant self-administered test consists of four 10-page booklets. Each page contains a different scratch-and-sniff scented strip and an associated multiple-choice question. Photo courtesy of Sensonics, Inc. © 2000 Sensonics, Inc.
Journal of Allergy and Clinical Immunology  , S390-S413DOI: ( /j.jaci )
Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

6. Fig 5
Change in olfactory test scores with the UPSIT according to sex and age.
Journal of Allergy and Clinical Immunology  , S390-S413DOI: ( /j.jaci )
Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

7. Fig 6
STT. Concentrations of PEA, ranging from 10−2 to 10−10 log vol/vol in half-log concentration steps, are provided, along with blanks for forced-choice testing. Photo courtesy of Sensonics, Inc. © 2000 Sensonics, Inc.
Journal of Allergy and Clinical Immunology  , S390-S413DOI: ( /j.jaci )
Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

8. Fig 7
Lack of effect of fexofenadine 360 mg administered at 3 times the standard clinical dose for allergic rhinitis on a range of objective outcome measures of CNS psychomotor function in comparison with placebo and an active control, promethazine 30 mg. Impairment was seen with the active control in 15 subjects in (A) total reaction time (TRT), (B) critical flicker fusion (CFF), (C) recognition reaction time (RRT), and (D) compensatory tracking task (CTT). ∗P < 0.05 versus placebo. +P < 0.05 versus fexofenadine. Reproduced with permission from Blackwell Publishing.126
Journal of Allergy and Clinical Immunology  , S390-S413DOI: ( /j.jaci )
Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

9. Fig 8
Influence of age and therapy on crude rates per 10,000 for life-threatening ventricular arrhythmias and cardiac arrest within the population. ∗P < 0.05 versus terfenadine. OTC, over the counter. Reprinted with permission from Pratt et al. Excerpta Medica. ©
Journal of Allergy and Clinical Immunology  , S390-S413DOI: ( /j.jaci )
Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

10. Fig 9
Change in height over 1 year in children treated with beclomethasone diproprionate 200 μg twice daily or placebo showing a significant reduction in growth in those receiving the intranasal steroid. Asterisks indicate time-points of significant difference between active and placebo therapy. BDP, beclomethasone dipropionate. Reproduced with permission from Pediatrics, Vol 105(2), page E23. © 2000 by the AAP.178
Journal of Allergy and Clinical Immunology  , S390-S413DOI: ( /j.jaci )
Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

11. Fig 10
Change in height over 1 year in children treated with intranasal mometasone or placebo showing no deleterious effect of this intranasal steroid on growth. ∗P < 0.05 for increased growth in mometasone-treated children. MFNS, mometasone furoate nasal spray. Reproduced with permission from Pediatrics, Vol 105(2), page E22. © 2000 by the AAP.179
Journal of Allergy and Clinical Immunology  , S390-S413DOI: ( /j.jaci )
Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions